Rocket Lab: I'm Doubling Down After The Crash

Rocket Lab fell to roughly $51, which the article characterizes as a better risk-reward setup, even as Neutron's inaugural launch slipped into 2027. Q2 revenue rose 62% to $234 million, backlog reached $2.36 billion, and Space Systems accounted for 81% of revenue. A first-stage tank problem underscores manufacturing maturity as the key risk; successful qualification is identified as the critical 2027 de-risking milestone.

Analysis

At roughly $51, the setup is more attractive only if investors separate the operating business from the Neutron option. Space Systems’ dominant revenue contribution can cushion a launch delay, but it also means consolidated growth and backlog do not yet prove Neutron’s manufacturing readiness or economics. The tank issue matters beyond timing: repeated hardware rework would point to process maturity and cost risk, potentially raising the capital and time required before Neutron can compete effectively with SpaceX and other launch providers.

Near term, the 2027 slip can keep a schedule-risk discount on RKLB; a quick recovery in the share price without evidence of manufacturing progress may be fragile. Over 1–3 months, monitor backlog conversion, Space Systems segment margins, cash use, and any revised Neutron milestones. Over 6–18 months, successful tank qualification would reduce execution risk, while another failure could pressure valuation and divert resources from the established business. The article does not provide valuation, cash runway, segment profitability, or backlog composition, so it cannot establish that the risk/reward is attractive on price alone. Contrarian angle: a large backlog is not equivalent to profitable, timely revenue, but treating all Neutron delay as evidence of a broken program may also underweight the continuing value of the non-Neutron business.

Key Decisions for Investors

• Do not buy solely on the quoted price or headline backlog. Before initiating, verify cash runway and financing needs, Space Systems segment margin trend, backlog conversion/cancellation terms, and Neutron-specific spending.
• Watchlist a staged RKLB long rather than a full position: add only after a verifiable Neutron manufacturing/qualification milestone and continued healthy Space Systems execution. Treat another tank-related qualification failure or a material deterioration in backlog conversion or segment margins as thesis-invalidating signals.
• For the next 1–3 months, avoid paying up for a schedule-driven bounce without milestone evidence. Reassess after company updates on tank qualification, cash use, and segment performance; do not infer Neutron readiness from consolidated revenue growth.